RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $55 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams reiterates an Outperform rating on Xenon Pharmaceuticals (NASDAQ:XENE) and maintains a $55 price target.
June 18, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams reiterates an Outperform rating on Xenon Pharmaceuticals and maintains a $55 price target.
The reiteration of an Outperform rating and a maintained price target of $55 by RBC Capital is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100